Vocxi Health

Vocxi Health is a diagnostic startup focused on transforming early disease detection through breath-based testing, anchored in its proprietary MyBreathPrint® technology. Originating from more than a decade of collaboration between a global medical device company and a world-class research institution, the company was formally incorporated in 2022 to bring a noninvasive, highly sensitive breath sensor to market. 

By analyzing volatile organic compounds (VOCs) in human breath using graphene-based nanosensors, advanced electrochemistry, and machine learning, Vocxi Health aims to provide an accessible, accurate view of patient health without needles, radiation, or prolonged waiting.

The company’s mission is to create the most accessible, accurate breath sensor to detect disease as early as possible, particularly in conditions like lung cancer where 84% of cases are currently diagnosed too late and traditional screening methods are underused or carry their own risks. Building on more than ten years of R&D, human clinical studies initiated in 2018, and the leadership of a team that includes blood cancer survivor and CEO Ping Yeh, Vocxi Health brings together scientific, engineering, and clinical experts dedicated to making late-stage diagnosis a thing of the past.